10.22376/ijpbs.2019.10.1.p1-12 Volume 6 Issue 4 2015 (October - December) Increased incidence of antibiotic resistant lessThan i greaterThan S. aureus lessThan /i greaterThan infections has spurred the need for new antimicrobial agents. Lysostaphin is an antistaphylococcal agent, which cleaves the pentaglycine cross bridges of lessThan i greaterThan S. aureus lessThan /i greaterThan cell wall leading to its lysis. Antimicrobial activity of r-lysostaphin was tested against 73 MRSA isolates by the disc diffusion assay and minimum inhibition concentration. Burn wound MRSA infected mice were treated with mupirocin and r-lysostaphin for a period of 5 days. All the MRSA isolates were sensitive to r-lysostaphin (50 µg/disc) with a zone of inhibition ranging from 14 to 17 mm and the MIC ranged between 0.25 to 2 µg/ml. The MRSA count in untreated group was 10 lessThan sup greaterThan 8 lessThan /sup greaterThan CFUs/g tissue. Mupirocin showed 3 log reduction (10 lessThan sup greaterThan 5 lessThan /sup greaterThan CFUs/g tissue) in bacterial count and r-lysostaphin significantly reduced greaterThan 5 log (10 lessThan sup greaterThan 3 lessThan /sup greaterThan CFUs/g tissue) in bacterial count as compared to the untreated group. Hence, r-Lysostaphin can be used as an effective alternative treatment for MRSA infections. NAGALAKSHMI NARASIMHASWAMY, INDIRA BAIRY, SYED MUSHARRAF, SWAPNIL KUMAR, USHA Y NAYAK, GAUTHAM SHENOY AND LAXMINARAYANA K BAIRY Antibiotic resistance, Methicillin Resistant Staphylococcus aureus (MRSA), Recombinant Lysostaphin (r-lysostaphin), Burn wound infection 1151-1157